Login Register Cart 0
Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspectives in Medicinal Chemistry

A Brief Overview on HIV Infection, Diagnosis and Treatment

Author(s): Mrinmoy Saha* and Shreya Bhattacharya*

Volume 19, Issue 30, 2019

Page: [2739 - 2741] Pages: 3

DOI: 10.2174/156802661930200103091335

Next »
[1]
HIV.gov. Global Statistics. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics
[2]
Hemelaar, J. The origin and diversity of the HIV-1 pandemic. Trends Mol. Med., 2012, 18(3), 182-192.
[3]
Lu, K.; Heng, X.; Summers, M.F. Structural determinants and mechanism of HIV-1 genome packaging. J. Mol. Biol., 2011, 410(4), 609-633.
[4]
Goodsell, D.S. Illustrations of the HIV life cycle. Curr. Top. Microbiol. Immunol., 2015, 389, 243-252.
[5]
Parekh, B.S.; Ou, C.Y.; Fonjungo, P.N.; Kalou, M.B.; Rottinghaus, E.; Puren, A.; Alexander, H.; Hurlston Cox, M.; Nkengasong, J.N. Diagnosis of human immunodeficiency virus infection. Clin. Microbiol. Rev., 2019, 32(1), pii: e00064-18.
[6]
AIDS info. The stages of HIV infection. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/19/46/the-stages-of-hiv-infection
[7]
AIDS info. HIV treatment. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines
[8]
Lu, D.Y.; Wu, H.Y.; Yarla, N.S.; Xu, B.; Ding, J.; Lu, T.R. HAART in HIV/AIDS treatments: future trends. Infect. Disord. Drug Targets, 2018, 18(1), 15-22.
[9]
Saha, M.; Bhattacharya, S. Recent developments in the medicinal chemistry for new small-molecule therapeutics to treat HIV-AIDS. Curr. Top. Med. Chem., 2019, 19(18), 1569-1570.
[10]
Riddell, J.t.; Amico, K.R.; Mayer, K.H. HIV Preexposure prophylaxis: a review. JAMA, 2018, 319(12), 1261-1268.
[11]
Zhan, P.; Pannecouque, C.; De Clercq, E.; Liu, X. Anti-HIV drug discovery and development: current innovations and future trends. J. Med. Chem., 2016, 59(7), 2849-2878.
[12]
Hartman, T.L.; Yang, L.; Helfrick, A.N.; Hassink, M.; Shank, N.I.; George Rosenker, K.; Scerba, M.T.; Saha, M.; Hughes, E.; Wang, A.Q.; Xu, X.; Gupta, P.; Buckheit, R.W., Jr; Appella, D.H. Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus. Antiviral Res., 2016, 134, 216-225.
[13]
Saha, M.; Scerba, M.T.; Shank, N.I.; Hartman, T.L.; Buchholz, C.A.; Buckheit, R.W., Jr; Durell, S.R.; Appella, D.H. Probing mercaptoben- zamides as HIV inactivators via nucleocapsid protein 7. ChemMedChem, 2017, 12(10), 714-721.
[14]
Nikolayevskiy, H.; Robello, M.; Scerba, M.T.; Pasternak, E.H.; Saha, M.; Hartman, T.L.; Buchholz, C.A.; Buckheit, R.W., Jr; Durell, S.R.; Appella, D.H. The structure-activity profile of mercaptobenzamides’ anti-HIV activity suggests that thermodynamics of metabolism is more important than binding affinity to the target. Eur. J. Med. Chem., 2019, 178, 818-837.
[15]
Sancineto, L.; Iraci, N.; Tabarrini, O.; Santi, C. NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors. Drug Discov. Today, 2018, 23(2), 260-271.

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy